Evidence map›Paper›PMID 29805669›Full record

ArticleOncology letters2018

Oldhamianoside II inhibits prostate cancer progression via regulation of EMT and the Wnt/β-catenin signaling pathway.

Kaizhi Li, Xuemei Zhan, Jingyong Sun, Tianfeng Wang, Hongyan Dong, Fanbo Jing, Dongmei Li, Yu Cao, Yali Liu, Lin Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Wnt/β-catenin-driven EMT regulation in human cancers.Cellular and molecular life sciences : CMLS · 2024
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kaizhi LiDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, P.R. China.
Xuemei ZhanDepartment of Pathology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China.
Jingyong SunDepartment of Pharmacology, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Tianfeng WangDepartment of Hepatobiliary Surgery, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China.
Hongyan DongDepartment of Pathology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China.
Fanbo JingDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Dongmei LiDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Yu CaoDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Yali LiuDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Lin WangShandong Medical Biotechnological Center, Key Laboratory for Rare and Uncommon Diseases of Shandong Province, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Shengnan LiDepartment of Pharmacy, The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oldhamianoside II is a novel triterpenoidsaponin that can be isolated from the roots of

Indexed as

epithelial-mesenchymal transitionoldhamianoside IIprostate cancerβ-catenin

Identifiers

PMID29805669
PMCPMC5958739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.